Form 4: IGM Biosciences Chief Business Officer Sells Shares to Cover Tax Obligations

Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, sold 1,063 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Lisa Lynn Decker, the Chief Business Officer of IGM Biosciences, sold 1,063 shares of the company's common stock on December 16, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $7.48, with individual trades ranging from $7.00 to $7.84.
• Following the transaction, Ms. Decker beneficially owns 78,041 shares of IGM Biosciences common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine transaction for company executives to manage their personal finances and tax obligations related to equity compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many executives in similar roles at comparable companies such as BioMarin Pharmaceutical and Regeneron Pharmaceuticals regularly execute similar transactions.
• These transactions are typically disclosed via SEC Form 4 filings, which is standard practice for publicly traded companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a routine transaction.
• The transaction does not have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

IGM Biosciences, Lisa Lynn Decker, stock sale, insider trading, Form 4, restricted stock units, tax obligations, share transaction